The moment AbbVie 's (NYSE: ABBV) shareholders have been dreading for years is finally coming. In late January, the company will start facing generic competition in the U.S. for its best-selling product, immunology drug Humira. Humira has been AbbVie's key asset since it became a stand-alone company in 2013.
The pharma giant was able to survive Humira's loss of exclusivity in Europe in 2018 thanks to growing sales in the U.S. But the medicine's revenue will start dropping in the country soon, which could impact one of AbbVie's best selling points: the company's attractive dividend. Is it time for investors to look elsewhere?
For further details see:
With Competition on the Rise, Is AbbVie's Dividend Safe?